ArticleJournal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract2007
Surgical outcomes of gastrointestinal sarcoma including gastrointestinal stromal tumors: a population-based examination.
Article in Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Transvaginal resection of a gastrointestinal stromal tumor of the rectum: a case report.Surgical case reports · 2024Article
- Editorial: Improving post-surgical outcomes for patients with primary gastrointestinal stromal tumors.Frontiers in oncology · 2023Article
- Is the Surgical Margin in Gastrointestinal Stromal Tumors Different?Visceral medicine · 2018Review
- Current treatment strategies in pediatric gastrointestinal stromal cell tumor.Translational gastroenterology and hepatology · 2018Review
- Osteosarcoma: improvement in survival limited to high-grade patients only.Journal of cancer research and clinical oncology · 2011Article
- Prognostic factors for survival in patients with epithelioid sarcoma: 441 cases from the SEER database.Clinical orthopaedics and related research · 2009Article
- Outcomes of malignant CNS ependymomas: an examination of 2408 cases through the Surveillance, Epidemiology, and End Results (SEER) database (1973-2005).The Journal of surgical research · 2009Article
- Impact of KIT and PDGFRA gene mutations on prognosis of patients with gastrointestinal stromal tumors after complete primary tumor resection.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2009Article
- Surgical outcomes of patients with gastrointestinal stromal tumors in the era of targeted drug therapy.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2008Article
- p16 expression differentiates high-risk gastrointestinal stromal tumor and predicts poor outcome.Neoplasia (New York, N.Y.) · 2008Article
- Defining the role of surgery for primary gastrointestinal tract melanoma.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe surgical approaches and outcomes for gastrointestinal sarcoma are determined largely from single institutional series.
objectiveWe sought to determine patient outcomes after different surgical approaches for gastrointestinal sarcomas, including gastrointestinal stromal tumors (GIST), utilizing a large prospective cancer registry. MATERIAL AND
methodsThe Surveillance, Epidemiology, and End Results (SEER) database was queried from 1991 to 2002.
resultsOverall, 1873 gastrointestinal mesenchymal tumors were identified in the SEER data set, with 82% GIST and 18% smooth muscle neoplasms. Surgery was performed in 83% of the cohort. Median survival was 68 months for complete resection (CR), 51 months for partial resection (PR), and 10 months for no resection (NR) (P < 0.001 each category). Outcomes within the CR group were equivalent for wedge or total organ removal. Median survival rates for localized, regionally advanced, and metastatic disease were 97, 35, and 18 months, respectively, after CR, and in all cases significantly improved relative to patients not undergoing resection. Median survival rates in patients treated after 2000 have substantially improved in this cohort, possibly reflecting the impact of imatinib on overall population-based survival. Multivariate analysis identified organ, histologic grade, surgical resection, and date of surgery (pre-2000 or post-2000) as independent predictors of survival.
conclusionsThe outcomes after surgical therapy for gastrointestinal sarcomas, including GIST, support the operative goal of a complete resection. Improved outcomes after 2000 indicate the potential benefit of newer therapies, including imatinib.
Indexed as
Identifiers
17390197What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.